ירדן -
אנגלית -
JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)
calquence 100mg capsule 100 mg/1 cap
مستودع ادوية شاوي و رشيدات و مسنات - shawi & rushedat drug store - acalabrutinib 100 mg/1 cap - 100 mg/1 cap
בנגלדש -
אנגלית -
DGDA (Directorate General of Drug Administration)
calcent 100 capsule
incepta pharmaceuticals ltd. - acalabrutinib - capsule - 100 mg
בנגלדש -
אנגלית -
DGDA (Directorate General of Drug Administration)
acanix capsule
beacon pharmaceuticals plc - acalabrutinib - capsule - 100 mg
בנגלדש -
אנגלית -
DGDA (Directorate General of Drug Administration)
acaluxen capsule
everest pharmaceuticals ltd. - acalabrutinib - capsule - 100 mg
פיליפינים -
אנגלית -
FDA (Food And Drug Administration)
calquence 100 mg capsule
astrazeneca ab; distributor: astrazenecapharmaceuticals (phils.), inc. - acalabrutinib - capsule - 100 mg
יפן -
אנגלית -
すりの適正使用協議会 RAD-AR Council, Japan
calquence capsules 100mg (カルケンスカプセル100mg)
astrazeneca k.k - acalabrutinib - blue and yellow capsule, major axis: approx. 19.4 mm, minor axis: approx. 6.9 mm
ערב הסעודית -
אנגלית -
SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء
calquence film-coated tablet
astrazeneca uk limited, united kingdom - acalabrutinib - film-coated tablet - 100 mg,
דרום אפריקה -
אנגלית -
South African Health Products Regulatory Authority (SAHPRA)
calquence capsules
astrazeneca pharmaceuticals (pty) ltd - capsules - see ingredients - each capsule contains acalabrutinib 100,0 mg
קנדה -
אנגלית -
Health Canada
tecartus suspension
gilead sciences canada inc - brexucabtagene autoleucel - suspension - 200000000cells - brexucabtagene autoleucel 200000000cells - antineoplastic agents
אוסטרליה -
אנגלית -
Department of Health (Therapeutic Goods Administration)
cellular therapies
gilead sciences pty ltd - brexucabtagene autoleucel, quantity: 1000000 cells/kg - injection, intravenous infusion - excipient ingredients: albumin; dimethyl sulfoxide; sodium chloride - cellular therapies - tecartus is a genetically modified autologous immunocellular therapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (mcl), who have received two or more lines of therapy, including a btk inhibitor, unless ineligible or intolerant to treatment with a btk inhibitor.